Episode Details

Eli Lilly, the pharmaceutical giant behind Mounjaro, is ready to resume UK investments, but only if the government agrees to regular NHS drug price increases and abandons a contentious rebate scheme. Theyre advocating for new pricing models, such as linking payments to real-world results, like improved work productivity post-treatment. This move follows US pharma giants pressure, as UK Prime Minister Keir Starmer approved the first NHS cost-effectiveness threshold hike in 27 years. Last year, Eli Lilly and others halted nearly £25 billion worth of UK projects, including a central London lab site. The company argues UK medicine prices have been too low for over two decades, requiring clear timelines and actions for progress. Meanwhile, discussions emphasize how obesity drugs like Mounjaro reduce workplace absenteeism, with 2.8 million eligible UK workers absent due to illness. A pill version is set to launch later this year, with plans for outcome-based deals to broaden access. The government maintains these pricing adjustments will expedite NHS access to advanced treatments for thousands, while adhering to the UK-US deal that increases payments by 25% by 2035, all from the NHS budget.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/b02277f0017c8127